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Abstract
The genetic alterations in cancer cells are tightly linked to signaling pathway dysregulation. Ras is a key molecule that controls
several tumorigenesis-related processes, and mutations in RAS genes often lead to unbiased intensification of signaling networks
that fuel cancer progression. In this article, we review recent studies that describe mutant Ras-regulated signaling routes and their
cross-talk. In addition to the two main Ras-driven signaling pathways, i.e., the RAF/MEK/ERK and PI3K/AKT/mTOR path-
ways, we have also collected emerging data showing the importance of Ras in other signaling pathways, including the RAC/
PAK, RalGDS/Ral, and PKC/PLC signaling pathways. Moreover, microRNA-regulated Ras-associated signaling pathways are
also discussed to highlight the importance of Ras regulation in cancer. Finally, emerging data show that the signal alterations in
specific cell types, such as cancer stem cells, could promote cancer development. Therefore, we also cover the up-to-date findings
related to Ras-regulated signal transduction in cancer stem cells.
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1 Introduction
Since the discovery of Ras as a key regulator of retrovirus-
induced cell proliferation, a massive scientific effort has been
devoted to identifying its critical roles in biology, especially in
oncogenesis. Ras proteins are specialized guanine nucleotide-
binding and hydrolyzingmolecules that belong to the small G-
protein superfamily [1]. The human genome contains three
highly related RAS genes, namely, KRAS (Kirsten rat sarco-
ma viral oncogene homolog), NRAS (neuroblastoma RAS
viral oncogene homolog), and HRAS (Harvey rat sarcoma
viral oncogene homolog), which encode four highly homolo-
gous proteins, namely, H-Ras, K-Ras4A and K-Ras4B (two
splice variants of K-Ras), and N-Ras. Ras proteins have a
molecular weight of approximately 21 kDa, and each contains
a soluble catalytic G-domain and a C-terminal flexible hyper-
variable region (HVR) (Fig. 1.)
The majority of the mutations in RAS genes that lead to
oncogenic events are single-base substitutions in well-
described positions in the G-domain. The most frequent on-
cogenic mutational hotspots are at codons 12, 13, and 61 in all
four Ras isoforms. Less frequently, other codons in RAS
genes are also affected by mutations, as summarized in
Table 1. Oncogenic mutations in the G-domain allow Ras
protein to constitutively activate downstream effectors.
Interestingly, the different amino acid substitutions in the mu-
tational hotspots distinctly alter the GTPase function of Ras
and its interactions with signaling molecules. Moreover, mu-
tant Ras proteins differently activate the RAF/MEK/ERK ki-
nase cascade and other non-canonical downstream signaling
molecules. The interdependence and cross-talk of downstream
effectors regulated by mutant Ras proteins and recent ad-
vances in understanding the broad spectrum of the effects of
Ras in cell biology are discussed here.
2 Structural basis of wild-type andmutant Ras
activation kinetics
Several studies have demonstrated that the Ras protein level is
elevated in cancer tissues and that increased Ras expression is
correlated with poor prognosis [32, 33]. As the mechanisms
regulating Ras protein level have significant pathological im-
plications, the factors and signaling pathways influencing the
stable and unstable degradable forms of Ras are possible de-
terminants of cancer progression. Ras stability depends on the
* Virag Vas
vas.virag@ttk.hu
1 Institute of Enzymology, Research Centre for Natural Sciences,
Budapest, Hungary
2 Department of Medical Chemistry, Semmelweis University Medical
School, Budapest, Hungary
Cancer and Metastasis Reviews
https://doi.org/10.1007/s10555-020-09912-8
phosphorylation status of the protein on two threonine resi-
dues at positions 144 and 148 (Fig. 1). Once Ras is phosphor-
ylated by GSK3β kinase at these positions, phospho-Ras can
bind the β-TrCP protein [34]. An E3 ligase recognizes the β-
TrCP-phospho-Ras complex and ubiquitinates Ras, thus lead-
ing to Ras degradation by the proteasome. [33] The regulation
of GSK3β kinase depends onWnt/β-catenin signaling to reg-
ulate the ubiquitination-dependent degradation of both the
wild-type and mutant forms of Ras [35]. Although
phosphorylation-dependent degradation presumably has a
role in the regulation of mutant and wild-type Ras protein
levels, interestingly, the mutational hotspots leading to Ras-
mediated cancer development do not affect the GSK3β-
targeted threonines in Ras. Therefore, it is highly probable
that the activation level of accessible Ras protein is the major
decisive factor in oncogenesis rather than the stability of Ras.
The active state of wild-type Ras depends on its intrinsic
ability to bind and hydrolyze GTP via the conserved 20-kDa
G-domain. The Ras intrinsic GTPase activity is accelerated by
the GEF/GAP system (guanine nucleotide exchange factors
and GTPase-activating proteins, respectively), which fuel the
cycling between inactive GDP-Ras and active GTP-Ras.
GEFs are the main activators of Ras via catalyzation of GDP
release and GTP loading in the GTPase domain. Ras can bind
Fig. 1 Schematic representation of Ras proteins. The GTPase domain
consists of six β-strands (red labeled) and five α-helices (blue labeled).
Three inter -β-strand and α-helix loops are highlighted, i.e., the P-loop,
the switch I, and the switch II regions. The P-loop binds the beta phos-
phate of guanosine phosphates. The switch I and switch II regions under-
go conformational changes during GTP-GDP hydrolysis and determine
the interactions of Ras partner proteins. The positions of the three most
frequent codon mutations are labeled with red letters, i.e., the glycines at
codons 12 and 13 and the glutamine at codon 61. The two threonines at
positions 144 and 148 (labeled with orange letters) can be phosphorylated
by GSK3β kinase and organize the ubiquitination of Ras to regulate
degradation. Each Ras protein has an isoform-specific hypervariable re-
gion (HVR) at the C-terminus that can be post-translationally modified
through palmitoylation, farnesylation, acetylation, methylation, or
prenylation. The sequences of the four HVR regions of K-Ras4B, K-
Ras4A, H-Ras, and N-Ras (depicted in blue) determine the PM and lipid
raft localization of Ras. The pie charts show the G12, G13, and Q61
mutation frequencies in the given isoforms
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Table 1 An overview of the signaling effects of the most highly studied RAS mutations
RAS isoforms and chromosome location Codon Amino acid substitution Signaling alterations
KRAS
Chromosome 12
Short arm, position 12.1
12: GGT (glycine) Alanine (G12A) No significant association with ERK activation [2]
Cysteine (G12C) Elevated MAPK signaling [3]
Aspartic acid (G12D) Increased GTP-bound state [4]; strong association
with ERK activation [2]; constitutively active
MAPK signaling [5]
Arginine (G12R) Decreased MAPK signaling [3]
Serine (G12S) Decreased MAPK signaling [3]; oncogenic effects
through overactive MAPK signaling and ELK1
activity [6]
Valine (G12V) Increased GTP-bound state [7]; no significant
association with ERK activation [2];
constitutively active MAPK signaling [5]
13: GGC (glycine) Cysteine (G13C) Increased GTP-bound state [7]
Aspartic acid (G13D) Fast GDP/GTP exchange [8]; constitutively active
MAPK signaling [5]
61: CAA (glutamine) Histidine (Q61H) No significant association with ERK activation [2]
Leucine (Q61L) Elevated ERK phosphorylation, low level of
GAP-mediated hydrolysis [8]
14: GTA (valine) Isoleucine (V14I) Increased GTP-bound state [9]
18: GCC (alanine) Aspartic acid (A18D) No significant change in GTP-bound state [7]
19: TTG (leucine) Phenylalanine (L19F) Increased GTP-bound state [10]
22: CAG (glutamine) Lysine (Q22K) Increased GTP-bound state [4]
59: GCA (alanine) Threonine (A59T) Oncogenic effects through overactive MAPK
signaling and ELK1 activity [6]
117: AAA (lysine) Asparagine (K117N) Moderate increase in GTP-bound state,
elevated ERK phosphorylation [4]
146: GCA (alanine) Threonine (A146T) Moderate increase in GTP-bound state,
elevated ERK phosphorylation [4]
HRAS
Chromosome 11
Short arm, position 5
12: GGC (glycine) Alanine (G12A) Increased GTP-bound state and no change in
MAPK signaling, enhanced PI3K signaling [11]
Increased GTP-bound state, enhanced ERK
and c-Jun N-terminal kinase activity [12]
Cysteine (G12C) Increased GTP-bound state, enhanced ERK
and c-Jun N-terminal kinase activity [12]
Aspartic acid (G12D) Increased GTP-bound state, enhanced ERK
and c-Jun N-terminal kinase activity [12]
Arginine (G12R) Upregulation of the MKP3 gene via the activation
of the PI3K-AKT pathway causing impaired
FGF2-induced ERK1/2 phosphorylation [13]
Serine (G12S) Increased GTP-bound state, enhanced MAPK
signaling, and strong phosphorylation of AKT
in COS-7 cells, while no change in MAPK
signaling and enhanced PI3K signaling in
patient-derived cells [11]; increased GTP-bound
state, enhanced ERK and c-Jun N-terminal
kinase activity [12]
Valine (G12V) Constitutively active MAPK signaling [5];
enhanced MAPK signaling [14]; increased
GTP-bound state, enhanced MAPK signaling,
and strong phosphorylation of AKT in mutant
COS-7 cells, while no change in MAPK
signaling and enhanced PI3K signaling in
patient-derived cells [11]; increased GTP-bound
state, enhanced ERK and c-Jun N-terminal
kinase activity [12]
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GTP with high affinity, and GEFs can sterically displace the
catalytic magnesium ion from the G-domain and restructure
the nucleotide binding site, thus leading to the exchange of
GDP to GTP. To downregulate Ras signaling, GAP proteins
accelerate Ras-dependent GTP hydrolysis. A common feature
of oncogenic Ras mutations is that they affect the nucleotide-
binding site of Ras and lead to aberrant constitutive activation.
The most common mutations, which are in codons 12, 13, and
61, lie in the G-loops of the protein by which Ras interacts
with GDP and GTP. Although it is widely accepted that most
Table 1 (continued)
RAS isoforms and chromosome location Codon Amino acid substitution Signaling alterations
13: GGT (glycine) Cysteine (G13C) Increased GTP-bound state, no change in MAPK
signaling, enhanced PI3K signaling [11];
increased GTP-bound state, enhanced ERK and
c-Jun N-terminal kinase activity [12]
Aspartic acid (G13D) Increased GTP-bound state, no change in MAPK
signaling, enhanced PI3K signaling [11];
increased GTP-bound state, enhanced ERK
and c-Jun N-terminal kinase activity [12]
Arginine (G13R) Constitutive activation of MAPK signaling [15];
constitutive activation of MAPK signaling [16]
61: CAG (glutamine) Lysine (Q61K) Enhanced PI3KAKT-mTOR and MAPK
signaling [17]; constitutive activation of
MAPK signaling [16]
Leucine (Q61L) Enhanced MAPK signaling [18]
Arginine (Q61R) Increased GTP-bound state, enhanced
PI3KAKT-mTOR and MAPK signaling [17, 19];
constitutive activation of MAPK signaling [16]
NRAS
Chromosome
Short arm, position 13.2
12: GGT (glycine) Aspartic acid (G12D) Activation of MAPK signaling [20]
Oncogenic effects independent from MAPK
signaling and ELK1 activity [6]
Serine (G12S) Effects on NRAS function have not been
elucidated [21]
Valine (G12V) Induction of PI3K/AKT/rS6 signaling [22];
enhanced MAPK signaling [14];increased
GTP-bound state, upregulated MAPK signaling
and AKT phosphorylation [23]
13: GGT (glycine) Aspartic acid (G13D) Induction of MAPK signaling [24]; no significant
association with ERK activation [2]
Arginine (G13R) No significant association with ERK activation [2]
61: CAA (glutamine) Histidine (Q61H) MEK-independent regulation of ERK:
phosphorylation of ERK1/2 without phosphorylation
of MEK1/2 [25]; no significant association with
ERK activation [2]
Lysine (Q61K) Enhanced MAPK signaling [26]; no significant
association with ERK activation [2]
Leucine (Q61L) Enhanced MAPK signaling [22]
Proline (Q61P) Increased GTP-bound state [27]
Arginine (Q61R) Activation of MAPK and PI3K-AKT-mTOR
signaling [28]; no significant association with
ERK activation [2]
60: GGA (glycine) Glutamic acid (G60E) Increased GTP-bound state [29]; increased GTP-bound
state, upregulated MAPK signaling, and no effect
on AKT phosphorylation [23]
146: GCC (alanine) Threonine (A146T) Increased levels of activated Ras, hyperactive MAPK
signaling, enhanced PI3K signaling [30]
The data presented here sometimes appear contradictory, possibly due to differences in the model systems used, e.g., expression of the mutant gene
(ectopic vs. endogenous, transient vs. sustained), the use of cell lines or patient-derived cells, different culture conditions (mediumwith or without serum,
use of different growth factors), or the cell context (transformed vs. untransformed environments) in which the mutations exert their effects. All of these
factors can contribute to the signaling alterations observed for each mutation present in Ras proteins [14, 23, 31].
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Ras mutations stabilize the protein in its active state and pro-
long its downstream signaling, less is known about the mech-
anisms by which each unique nucleotide substitution can in-
fluence Ras signalome activation. Here we assembled the cur-
rent evidence regarding how specific single-nucleotide substi-
tutions in mutant Ras help to maintain the protein in its active
state. It is already known that point mutations can directly
prolong the GTP-bound state of Ras as reported in two inde-
pendent studies comparing the features of different Ras mu-
tants. Stolze et al. reported (based on the work in MCF10A
cells) that the G13C, G12C, and G12V substitutions, along
with two rare substitutions (Q61H and K117N), lead to higher
levels of GTP binding relative to that of wild-type Ras [7].
Additionally, Janakiraman et al. found that when the G12D
and Q22K mutations were present in HEK-293T cells, Ras
was more robustly preserved in a GTP-bound state [4]. One
mechanism behind how mutant Ras remains constitutively
activated is via a reduction in its intrinsic GTPase activity, as
reported by Hunter et al. for single-nucleotide substitutions in
codon 12. They showed that most Ras proteins carrying dif-
ferent mutations at codon 12 have dramatically decreased rates
of intrinsic GTP hydrolysis [8, 36]. Furthermore, characteriza-
tion of another frequently mutated codon at position 61 also
revealed decreased intrinsic GTPase activity [37, 38].
Consistent with this concept, in addition to effects on the in-
trinsic activity, several Ras mutants have slower GAP-
mediated GTP hydrolysis rates [8]. The significant GAP-
insensitive property of mutant Ras, combined with its im-
paired intrinsic GTPase activity, allows it to remain longer in
the GTP-bound active state (Fig. 2). It was also recently shown
that mutant Ras can increase the level of activated wild-type
Ras [39]. In line with this concept, Jeng et al. found that G12V
mutant KRas upregulates wild type H-Ras and N-Ras activa-
tion level. They also showed that SOS (a GEF for Ras) can
mediate such cross-activation by serving as a binding platform
between mutant and wild-type Ras [39]. Last but not least, a
faster GDP to GTP exchange rate is also a possible mechanism
allowing constitutive activation of mutant Ras. For example, it
has been demonstrated that the intrinsic GEF-independent
GDP exchange rate in G13D K-Ras mutant is an order of
magnitude higher than that of wild-type Ras [8, 40].
3 Specialties of mutant Ras-driven signaling
In the presence of growth factors (GFs), several intracellular
signaling pathways are initiated in normal cells. In the first
step, GF binding converts the receptor into an active state
Fig. 2 Schematic representation of the mechanism leading to
constitutively active forms of mutant Ras. The transition from inactive
GDP-bound to active GTP-bound Ras is regulated by several factors,
including GEFs and GAPs. Oncogenic mutant Ras proteins could remain
in a prolonged active form. Mutations in Ras can result in an accelerated
intrinsic GDP/GTP exchange rate or impairment of its intrinsic hydrolytic
activity. In addition to changing the intrinsic enzymatic activity of Ras,
oncogenic Ras mutations can also alter its sensitivity to GAP and GEF
activity
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via autophosphorylation and dimerization, leading to recruit-
ment of adaptor proteins such as Grb2 and Shc to the dimer’s
cytoplasmic tail. Via Grb2, GEF proteins (e.g., SOS) can lo-
calize to the membrane and facilitate Ras activation. When
wild-type Ras is in its GTP-bound state, it can assemble dif-
ferent signaling molecules at the membrane. The various Ras-
associated effector proteins then promote canonical and non-
canonical downstream Ras signaling (Fig. 3).
4 The MAPK pathway
When Ras is activated by either GEFs or mutations,
GTP-bound Ras undergoes conformational changes in
the switch regions that allow RAF binding. RAF acti-
vation requires dimerization of GTP-bound Ras mole-
cules. In the case of constitutively active mutant Ras
and its dimers, the size of the membrane nanoclusters
increases and more RAF molecules can be recruited.
Therefore, under Ras mutant oncogenic conditions,
Ras-dependent RAF signal transduction can be robustly
amplified. RAF is a serine/threonine kinase with three
paralogs, i.e., A-RAF, B-RAF, and C-RAF. Among
them, A-RAF has the lowest and B-RAF has the highest
kinase activity [41]. Notably, like Ras, RAF proteins are
also oncogenes, and B-RAF is the most frequent mutant
RAF variant in cancers [42]. Mutant RAF proteins ei-
ther bypass the Ras-initiated RAF dimerization step for
their activation or have increased kinase activity, and
oncogenic RAF mutations can lead to enhanced signal-
ing via both mechanisms [43]. Dimerized GTP-Ras al-
lows RAF to be released from its autoinhibited state.
RAF kinase domains activate mitogen-activated and ex-
tracellular signal-regulated kinases (MEK) by phosphor-
ylating two conserved serine residues in the catalytic
domain of MEK. At this step in the MAPK pathway,
the MEK subtypes MEK1 and MEK2 dual-specificity
kinases can catalyze the phosphorylation of ERK1 and
ERK2 on threonine and tyrosine residues. The next step
in MAPK signaling involves a branching in the signal
propagation pathway after which ERK mediates the
phosphorylation of multiple cytoskeletal, cytoplasmic,
and nuclear partner molecules. The most studied molec-
ular targets of ERK kinase activity are nuclear
Fig. 3 Signaling networks
involved in Ras-driven oncogen-
esis. This figure summarizes the
core members of the signaling
pathways radiating from mutant
Ras. The two robust Ras-driven
signaling routes are the RAF/
MEK/ERK and PI3K/AKT path-
ways, which regulate diverse cel-
lular processes, particularly cell
proliferation and cell survival
regulation, respectively. Other
Ras activation-dependent signal-
ing routes are less studied. The
TIAM1/RAC/PAK pathway pri-
marily controls cytoskeleton rear-
rangement in certain cells, and the
RalGDS/Ral pathway mostly in-
fluences membrane trafficking.
The NORE1/RASSF1/MST sig-
naling pathway is a regulator of
cell death processes. Mutant Ras
can also mediate signaling via
PLC/PKC molecules to influence
Ca+-dependent signaling in can-
cer cells
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transcription factors. Upon ERK phosphorylation, ERK
forms dimers and translocates to the nuclear membrane,
leading to modulation of c-Myc, c-Fos, c-Jun, and Elk-1
activities. When these transcription factors are activated
and bind to the promoters of their target genes, the
expression of well-known cell survival and cell cycle
regulators is induced. Additionally, cytoplasmic ERK
can modulate other signaling molecules, including cyto-
skeletal microtubule-associated proteins (MAPs), ribo-
somal s6 kinase (RSK), mitogen- and stress-activated
protein kinases (MSKs), and cytosolic phospholipase
A2 (Cpla2). ERK activation also represents a feedback
regulatory loop since ERK can hyperphosphorylate sig-
naling molecules upstream in the MAPK pathway. This
process is critical in the deregulation of the Ras-initiated
signaling as the hyperphosphorylation of GEFs (i.e.,
SOS1) disrupts their association with Ras and Ras lo-
calization at the membrane [44]. More than 250 ERK
target proteins have already been identified, highlighting
the robustness of the effects of ERK during MAPK
signaling (reviewed by [45]).
The ultimate outcome of the wild-type Ras-driven MAPK
pathway is context dependent and can also lead to the initiation
of diverse genetic programs associated with cell growth, cell
migration, cell cycle, and cell survival. Moreover, Ras and its
downstream MAPK effectors were also connected to the regu-
lation of circadian rhythm [46]. Since mutant Ras proteins are
in a constitutively active, GTP-bound state, one explanation for
their oncogenicity is that they initiate increased MAPK signal-
ing [47]. Although this presumption is highly likely to be valid,
not all Ras mutants accelerate the MAPK pathway. For in-
stance, Burd et al. showed that not all mutant NRAS proteins
(i.e., those with mutations at codons 12, 13, and 61) can induce
increased ERK phosphorylation [48]. A study that analyzed the
affinity of mutant Ras proteins for RAF demonstrated that
KRAS codon 12 mutants do not exhibit a very high affinity
for RAF even though their GTPase activity is low [8].
Riquelme et al. also confirmed that not all oncogenic K-Ras
mutants activate and enhanceMAPK signaling by showing that
the level of phospho-MEK1/2 is increased in NSCLC cells
harboring the KRAS G12C and KRAS G12D mutations but
decreased in cells harboring the KRAS G12R and G12S [3].
By contrast, a recent study using NIH3T3 cells showed that
KRAS G12S-expressing cells had elevated p-ERK levels, sug-
gesting that this mutant in this setting exerts its oncogenic phe-
notype via MAPK signaling [6].
Taken together, the data summarized here show that single
amino acid substitutions at codons 12, 13, or 61 in RAS can
stabilize the active GTP-bound state of RAS protein but that
not all mutations result in elevatedMAPK signaling (Table 1);
therefore, it is clear that this type of signaling is highly context
dependent and is influenced by the level of mutant Ras protein
or by the given cell type.
5 The PI3K/AKT/mTOR signaling pathway
The other major signaling pathway initiated by Ras is the
PI3Kα/AKT/mTOR pathway, and among many other cellular
processes, this pathway plays crucial roles in cell survival and
apoptosis inhibition [49].
It has been demonstrated that Ras isoforms differentially
activate the two canonical Ras signaling cascades and that there
are also differences between the specific Ras mutants in their
signal initiation. According to the model proposed by Nussinov
et al., the K-Ras4B isoform might be the most potent activator
of the PI3Kα/AKT pathway [50]. Based on the observations
that K-Ras4B can form a multimeric complex with CaM and
PI3Kα and that this mode of PI3K activation is independent of
the RTK signal, the authors proposed that K-Rasmost efficient-
ly triggers the PI3Kα/AKT pathway [51].
The PI3Kα protein is a lipid kinase consisting of catalytic
and regulatory subunits. It converts phosphatidylinositol
(4,5)-bisphosphate (PIP2) to phosphatidylinositol (3,4,5)-tris-
phosphate (PIP3) at the cell membrane. PI3Kα can directly
bind Ras via the Ras-binding domain (RBD) in its p110 cat-
alytic subunit, and this interaction leads to PI3Kα activation.
The mechanism of this activation remains unclear; however, it
has been established that PI3Kα recruitment to the cell mem-
brane by Ras has a key role since Ras can promote the forma-
tion of a preorganized PIP2-binding-favored state in the cata-
lytic subunit [52]. PIP3 is an important second messenger as it
recruits several signaling proteins, including transducing ki-
nases with pleckstrin homology domains, to the plasma mem-
brane. One such serine/threonine kinase is AKT (alternatively,
protein kinase B, PKB) and its activator PDK1 [53]. In the
presence of increased PIP3 levels, PDK is localized near AKT
and can phosphorylate the AKT molecule at the catalytic do-
main [54]. When mTOR complexes are also attracted to the
PIP3-enriched membrane, mTORC2 can phosphorylate AKT
in its hydrophobic domain [55]. Once AKT is activated and
released from the membrane-bound protein complex, the
downstream proliferative signals can be transmitted into the
cytosol. AKT has more than 200 binding partners, ranging
from the glucose intake regulator GSK3 to several cell
cycle-controlling complexes to the p53 inhibitor MDM2;
therefore, PI3K/AKT signaling has very diverse effects on cell
growth and survival [53, 56]. Orchestration of spatial and
temporal processes, such as complex signaling networks, re-
quires fine-tuning of the players at every step of the signaling
pathway. When Ras is mutated and the PI3K/AKT pathway is
deregulated, multitudes of signaling molecules are affected,
thus leading to uncontrolled cellular signaling [53].
It is not easy to investigate the involvement of Ras in the
PI3K pathway because PI3K can also be activated by many
other proteins independently from Ras, including G-protein-
coupled receptors (GPCRs) and receptor tyrosine kinases
(RTKs) [57]. However, the connection between Ras and
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PI3Kα seems to be essential, since blockage of their interac-
tion in EGFR mutant-driven lung cancer can block tumor
initiation and promote regression [58]. The PI3K pathway is
frequently upregulated in RAS mutant cells, although Ras
itself is insufficient to initiate PI3K-mediated tumorigenesis.
During tumorigenesis, mutant Ras can interact with specific
RTKs, and it has been shown that they can cooperatively
activate PI3K in human colorectal [59] and lung cancer cell
lines [60]. Inhibition of the PI3K pathway is insufficient to
block malignant transformation because of a mutual connec-
tion between the PI3K and the MAPK pathways with a feed-
back mechanism, i.e., if one of the pathways is blocked, the
second pathway is activated [61]. Therefore, to efficiently
treat Ras-driven cancers, combination therapies may prove
to be efficient.
We have already discussed how different amino acid substi-
tutions have distinct consequences for MAPK pathway activa-
tion. The same is true for PI3K/AKT signaling, as mutations in
Ras isoforms activate PI3K/AKT signaling with varying inten-
sities. In an earlier work, Yan et al. studied the PI3K-activating
potential of G12V mutant Ras isoforms, and they found that in
transduced COS cells, H-Ras G12V could more robustly acti-
vate PI3K than could K-Ras G12V [62]. While activated Ras
proteins trigger both the MAPK and PI3K/AKT pathways, the
mechanisms underlying the regulation of the intensity of each
pathway’s activation vary. For PI3K activation, the presence of
GTP-bound Ras is sufficient. By contrast, Ras dimerization and,
in the long term, Ras-formed microdomains are required for
RAF and MAPK cascade initiation [63].
6 Signaling via interactions between Ras
and the guanine nucleotide exchange factors
as TIAM1 or RalGDS
In addition to the two primary Ras-mediated pathways, Ras is
also involved in several other signaling modalities. One of the
less frequently studied pathways is RAC/PAK signaling.
Activated Ras can interact with the Ras-binding domain of
the TIAM1 protein (T lymphoma invasion and metastasis
protein) at the plasma membrane [64]. TIAM1 is a guanine
nucleotide exchange factor that facilitates the activation of
RAC proteins. Via TIAM1mediation, wild-type Ras can stim-
ulate the GDP-GTP exchange of RAC, ultimately leading to
the binding and phosphorylation of PAK serine threonine ki-
nases (p21-activated kinases) [65]. PAK exerts its effects on
many key regulatory proteins via phosphorylation, e.g., PI3K,
RAF, and β-catenin, and it modulates cell growth and surviv-
al; however, it acts predominantly in cytoskeleton rearrange-
ment and cell migration [66].
Mutant Ras can also upregulate RAC/PAK signaling. For
example, several studies found elevated RAC activity in mu-
tant HRAS-transformed fibroblasts [64, 67]. In a KRAS-
driven skin squamous cell carcinoma mouse model, deletion
of the PAK1 gene led to decreased tumor initiation and pro-
gression, thus indicating an important role for PAK1 in Ras
signaling [68]. Additionally, mutant HRAS-driven PAKs play
roles in cell cycle regulation by upregulating cyclin D1, a
major activator of the G1-S transition, and this upregulation
can cause malignant transformation [69]. PAKs are also in-
volved in PI3K and RAF signaling, as they can activate cer-
tain components of these pathways. In many cases, therapeu-
tic inhibition of the PI3K or RAF/MAPK pathways is ineffec-
tive [70, 71], perhaps in part due to PAK activation. Notably,
PAK can also activate AKT, revealing that interplay exists
between the major Ras pathways and RAC/PAK signaling.
It is plausible that combination therapies targeting mem-
bers of these pathways and PAKs could work by preventing
cross-activation; however, PAKs can act independently of the
two abovementioned signaling pathways, since in mutant
KRAS-driven colon cancer, knockdown of either PAK1 or
PAK4 inhibits cancer cell proliferation and increases apopto-
sis [72]. Unfortunately, we currently only know a few effec-
tors of RACs and PAKs, and the precise mechanisms by
which they influence cellular processes are poorly understood.
Given their significant roles in Ras-driven cancer, there is a
great need for further investigation of these pathways.
There is an additional Ras effector pathway in which the
initiation step of the signaling is triggered by an interaction
between Ras and a guanine nucleotide exchange factor.
RalGDS is a GEF for Ral and has also been identified as a
Ras-binding partner. When Ras is in its active, GTP-bound
state at the plasma membrane, RalGDS can bind to it to facil-
itate GDP to GTP exchange in Ral [73]. This mechanism is
similar with that of the Ras/TIAM1/RAC activation complex,
although Ras uses a non-Ras-specific GEF (e.g., TIAM1 and
RalGDS) for the signal transduction. The Ras/RalGDS/Ral
pathway was suggested to be involved in the regulation of
anchorage-independent growth of Ras-driven colon cancer
cells [74] and invadopodium formation of K-Ras mutant pan-
creatic adenocarcinoma [75].
7 Death signaling modulated by Ras
Ras is mainly known because of its role in promoting cell
survival and proliferation; however, in certain cases, mutant
Ras can inhibit cell growth, and it can lead to cellular senes-
cence or apoptosis [76, 77]. Matallanas et al. showed that
mutant K-Ras can enhance apoptosis in a p53-dependent man-
ner, and they suggested that wild-type K-Ras can counteract
this proapoptotic effect [78]. Other groups have suggested a
tumor suppressor role for wild-type K-Ras (rather than a
transformation-promoting function) in different cancer types
[79–81]. The context-dependent opposing effects of Ras are
not a unique phenomenon among oncogenes, and these
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diverse processes are either oncogene-induced senescence or
oncogene-induced apoptosis [82] [83–86].
Some key regulators of Ras-modulated cell death signaling
pathways belong to the RASSF protein family [87]. Themem-
bers of this family are scaffold proteins with no enzymatic
activity, and RASSF1A and NORE1A are the two most stud-
ied RASSF family members [88, 89]. RASSF proteins have a
Ras association (RA) domain by which Ras can directly acti-
vate them.
RASSF1A is one of the most frequently inactivated tumor
suppressors in human cancer, presumably because it connects
Ras signaling with apoptotic mechanisms [90, 91]. One of
these apoptotic pathways is linked to Hippo protein kinase
activation. RASSF1A can activate Hippo kinases, e.g.,
MST, leading to LAT kinase phosphorylation. At this step
of the RASSF/Hippo pathway, the YAP and TAZ transcrip-
tional regulators are recruited via phosphorylation, resulting in
enhanced transcription of proapoptotic genes [92]. Elevated
Ras activity can lead to cell death via apoptosis and prevent
malignant transformation; thus, it is not surprising that Ras-
driven tumors with RASSF1A inactivation have the poorest
prognosis [87, 93].
NORE1A is the closest RASSF1A homolog, and while it is
also a tumor suppressor, there are functional differences be-
tween the two proteins. While the main function of RASSF1A
is to mediate Ras-driven apoptosis, it seems likely that
NORE1A is primarily involved in cellular senescence (al-
though it can also regulate apoptosis) [87]. Cellular senes-
cence is a phenomenon that can prevent malignant transfor-
mation by arresting the cell cycle, as has been demonstrated
for p53 and Rb tumor suppressors [94]. NORE1A can activate
Rb via formation of a complex with PP1A, a phosphatase that
can dephosphorylate Rb to activate it [95]. NORE1A also
forms a complex with HIPK2, a kinase that can promote spe-
cific post-translational modifications of p53 that boost its
senescence-promoting activity [96]. All of these NORE1A
functions are regulated by Ras.
8 Ras and phospholipase C interact
in a signaling network
Phospholipase C (PLC) proteins are enzymes that can hydrolyze
phosphatidylinositol 4,5-bisphosphate (PIP2) in the plasma
membrane. This reaction produces two important intracellular
second messengers, i.e., diacylglycerol (DAG) and inositol
1,4,5-trisphosphate (IP3), that lead to the initiation of several
different downstream signaling pathways [97]. For instance,
DAGmediates the activation of PKC, amajor regulator of many
cellular processes, including proliferation, oncogenic stress-
induced apoptosis, and migration [98, 99]. Among the diverse
functions of PKC, its cell motility enhancement activity is
strongly linked to cancer development via its roles in controlling
cell invasion and metastasis [100]. PKC has also been implicat-
ed in integrin-dependent signaling [101] and phorbol ester-
induced cytoskeleton remodeling [102]. Furthermore, the
PKCα isoenzyme is also linked to the regulation of intracellular
trafficking by Ras, thereby modulating Ras-associated down-
stream signaling. Accordingly, PKCα can directly serine-
phosphorylate the K-Ras4B hypervariable domain leading to
Ras translocation from the cell membrane to the internal mem-
branes. Ultimately, this phosphorylation event on K-Ras4b pre-
vents signaling for survival and enhances proapoptotic mecha-
nisms in certain cell types [103, 104].
The other PLC product IP3 is responsible for initiating
Ca2+-dependent signaling in cells by enhancing Ca2+ release
from intracellular stores [105]. Only one PLC protein, i.e.,
phospholipase C epsilon (PLCε), is linked directly to Ras
[106]. PLCε has two Ras-associating domains (RA1 and
RA2), and activated Ras can bind to the RA2 domain. This
interaction markedly increases the enzymatic activity of PLCε
[107]. Interestingly, PLCε is not only a Ras effector, it can
also act as a Ras GEF via its CDC25 domain [108, 109]. Thus,
the signal transduction downstream of the Ras-PLCε signal-
ing node must be highly regulated; however, the precise
mechanism of this regulation and the role of Ras in the
Ca2+-dependent signaling network remain unclear. While it
is clear that Ras can alter PLCε activity in some types of
cancer [110], the role of PLCε in these disorders is unknown.
For example, according to Bai et al., PLCε is an oncogene in
H-Ras-triggered skin cancer [111]; however, a more recent
investigation by another group suggested the opposite.
Martins et al. concluded that PLCεmay be a tumor suppressor
in Ras-driven skin cancer based on their experiments in ge-
netically engineered mouse models [112].
9 Beyond the kinase cascades: the link
between Ras signaling and miRNAs
Investigations of the frequent downregulation of microRNAs
in various types of Ras mutant malignant cells led to the dis-
covery that several miRNAs target the oncogenic Ras path-
way. Since the primary functions of miRNAs are to limit
translation or enhance the degradation of specific mRNAs,
downregulation of Ras-targeting miRNAs could potentially
upregulate Ras protein levels. For example, in colorectal can-
cers, in which Ras is a frequent oncogenic driving force, it was
recently shown that the miR-143 level is decreased [113]. The
potent anti-Ras activity of microRNAs can be exploited in
tumor therapies. For example, Akao et al. showed that syn-
thetic miR-143 could be used to silence K-Ras mRNA and
that they could directly target AKT and ERK signaling in
DLD-1 cells [114]. In breast cancer cells, miR-200c (also a
Ras-targeting microRNA) affects various Ras pathway com-
ponents thereby influencing AKT and ERK phosphorylation
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[115]. MicroRNAs can alter the Ras pathway by decreasing
Ras mRNA translation; however, in some cases, a positive
correlation between the expression levels of a microRNA
and Ras has also been reported. It was recently observed that
both the miR-21 and K-Ras expression levels were elevated in
colorectal cancer samples, suggesting that, instead of sup-
pressing the Ras pathway, miR-21 may promote K-Ras
mRNA translation during cancer development [116]. Over
the last decade, the pleiotropic effects and biological signifi-
cance of microRNAs in Ras signaling modulation have been
established, and the use of microRNA levels as biomarkers for
cancer diagnosis is under extensive research [117, 118].
10 Altered Ras signaling by mutant Ras forms
in cancer stem cells
The cancer stem cell (CSC) concept proposes that tumor
growth, like the renewal of healthy tissues, is fueled by a small
subset of tumor cells endowed with stem cell characteristics.
Over the past decades, most solid and non-solid tumors have
been found to harbor CSCs or cells with stem cell (SC) fea-
tures, such as self-renewal and quiescence (with exceptions)
as well as expression of an often tumor-specific subset of SC
markers. It has been demonstrated that CSCs contribute to
tumor initiation, progression, metastasis, and therapy resis-
tance and that this processes could be linked to aberrant Ras
activation in CSCs [119, 120].
In colorectal cancer (CRC), a number of sequential genetic
alterations drive tumorigenesis. Activating mutations in the
KRAS gene alone do not usually induce transformation.
Initiating genetic mutations, such as a loss-of-function muta-
tion in the adenomatous polyposis coli (APC) gene, followed
by accumulation of activating mutations in the KRAS gene
are needed to drive tumorigenesis during the early and inter-
mediate phases of CRC. The resulting aberrant activation of
Wnt/β-catenin and Ras/ERK signaling are critical factors in
the transformation and disease progression [121]. Loss of
APC results in an initial activation of β-catenin signaling
and K-Ras stabilization; subsequently, the activated β-
catenin signaling is then further enhanced by stabilized mutant
K-Ras, thus creating a positive feedback loop that promotes
the development of CSC characteristics [121, 122]. Several
studies have shown that mutations in APC and KRAS (e.g.,
G12D) can result in pronounced increases in both Wnt/β-
catenin and Ras/ERK signaling activity, respectively, while
CSC characteristics, such as sphere-forming capacity and the
expression of CSCmarkers (i.e., CD44, CD133, and CD166),
are increased [35, 121, 122].
The therapeutic response to gemcitabine (GEM), a stan-
dard chemotherapeutic agent used in the treatment of pancre-
atic adenocarcinomas, has proven to be unsatisfactory.
Chemoresistance to GEM is associated with poor prognosis,
and the reacquisition of CSC-like features is considered to be a
main causative factor in the development of chemoresistance.
Zhao et al. demonstrated that the mechanism behind GEM’s
ineffectiveness was that after GEM induces NADPH oxidase
activation via nuclear factor κB (NFκB), activated NADPH
oxidase upregulates ROS production, which targets the K-
Ras/MAPK pathway. In KRAS knockdown experiments, K-
Ras was shown to be responsible for the GEM-mediated met-
abolic reprogramming and stemness of CSCs [123]. The K-
Ras/JNK axis was shown to play a central role in maintaining
CSCs or cancer stem-like cells (CSLCs) in pancreatic cancer
[124]. As another example of how Ras is involved in CSC
biology, Liu et al. [125] recently reported that urothelial car-
cinoma associated 1 (UCA1), a long noncoding RNA, is in-
volved in the upregulation of K-Ras expression and activity in
human pancreatic ductal adenocarcinoma cell lines. They
showed that UCA1 can increase K-Ras expression at both
the mRNA and protein levels by acting as a competing endog-
enous RNA sponging miR-590-3p, a suppressor of K-Ras
expression. Moreover, upregulated UCA1 could increase the
phospho-K-Ras level. Furthermore, sphere-formation assays
revealed that UCA1 was also responsible for stemness main-
tenance by affecting the expression levels of the stem cell
markers CD133, OCT4, Nanog, and SOX2 in human pancre-
atic ductal adenocarcinoma cell cultures [125], suggesting a
UCA1/K-Ras/cancer stemness relationship. A recent study by
Weng revealed additional Ras-mediated effects on CSCs and
demonstrated that G12D mutant KRAS enhanced CSC mark-
er expression (CD133, CD24, EpCAM) in prostate cancer
[126]. As these and other studies demonstrate, Ras is a central
player in CSC biology, and (depending on the type of tumor)
several different molecules/pathways are involved in regulat-
ing its effects on CSC preservation and enrichment [127].
11 Conclusions
Ras proteins coordinate multiple downstream effectors, many
of which are aberrantly activated during cancer development.
Although the regulatory roles of Ras proteins in signaling
networks are mostly linked to the RAF/MEK/ERK kinase
pathway and PI3K/AKT signaling, there is a growing evi-
dence that Ras also mediates other signaling routes under
normal and oncogenic conditions (Fig. 3). The four Ras iso-
forms differentially coordinate downstream effectors depend-
ing on their expression level or dimerization state. In addition
to the various effects of Ras isoforms on signaling intensity,
individual Ras mutants can strengthen or weaken signaling
routes differently (Table 1).
It has been recently established that one of the ultimate
challenges in anti-Ras therapy resides in Ras mutation-
specific differences; Therefore, studies investigating the dis-
tinct roles of each Ras mutant in signal transduction should be
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prioritized to discover additional promising Ras mutation-
selective therapeutic candidates.
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